๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed Peripheral T-Cell Lymphoma

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site๐Ÿ“ Singapore National Cancer Centre, Singapore ยท Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma NCT07075328Phase 1, Phase 25 sites๐Ÿ“ Fukuoka๐Ÿ“ Sapporo๐Ÿ“ Kagoshima Otsuka Medical Devices Co., Ltd. Japan ยท Tests: Drug:5-ALA, Device:Photodynamic system Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site๐Ÿ“ Shanghai Rong Tao ยท Tests: Tislelizumab, Zeprumetostat A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype NCT06522737Phase 344 sites๐Ÿ“ Ghent๐Ÿ“ Leuven๐Ÿ“ Prague SecuraBio ยท Tests: Duvelisib, Gemcitabine, Bendamustine CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: CD70 CAR-NK Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells NCT06420076Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD5/CD7 CAR-T Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492Phase 11 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: RD13-02 cell infusion Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma NCT04512534Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: PD-1 antibody+ HDAC inhibitor Polyspecific Antibodies in Lymphoproliferative T-cell Disorders NCT06495723Phase 1, Phase 28 sites๐Ÿ“ Caen๐Ÿ“ Clermont-Ferrand๐Ÿ“ Crรฉteil Xenothera SAS ยท Tests: LIS1 Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50) NCT06733051Phase 22 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Golidocitinib, Benmelstobart Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma NCT06934382Phase 11 site๐Ÿ“ Philadelphia Stephan Grupp MD PhD ยท Tests: Allogeneic anti-CD7 CAR-T cells (BEAM-201) Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma NCT06519526Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: SHR-0302, SHR-2554 A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL NCT06966154Phase 1, Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: tislezumab, golidocitinib, Selinexor Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma NCT06793956Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Sintilimab and Linperlisib Combination Treatment Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) NCT06810778Phase 1, Phase 21 site๐Ÿ“ Los Angeles Jonsson Comprehensive Cancer Center ยท Tests: Duvelisib, Venetoclax Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology NCT06378190Phase 1, Phase 28 sites๐Ÿ“ Barcelona๐Ÿ“ L'Hospitalet de Llobregat๐Ÿ“ Madrid Instituto de Investigaciรณn Biomรฉdica de Salamanca ยท Tests: CAR-T cells therapy Amping up With PemJAK NCT07283822Phase 21 site๐Ÿ“ New York Seda S. Tolu ยท Tests: Ruxolitinib, Pembrolizumab Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. NCT07598578EARLY Phase 11 site๐Ÿ“ Suzhou Second Affiliated Hospital of Soochow University ยท Tests: Azacitidine (AZA) To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL NCT07143929Phase 11 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CAR-T CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma NCT04083495Phase 22 sites๐Ÿ“ Chapel Hill๐Ÿ“ Winston-Salem UNC Lineberger Comprehensive Cancer Center ยท Tests: ATLCAR.CD30 T cells, Bendamustine, Fludarabine, Cyclophosphamide Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801n/a6 sites๐Ÿ“ Aurora๐Ÿ“ Atlanta๐Ÿ“ Cincinnati Children's Hospital Medical Center, Cincinnati ยท Tests: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid)โ€ฆ Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CD5-targeted CAR-T cells SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma NCT06122389Phase 31 site๐Ÿ“ Beijing Jiangsu HengRui Medicine Co., Ltd. ยท Tests: SHR2554; Chidamide analog tablets, SHR2554 analog tablets; Chidamide Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma NCT06561048Phase 337 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ San Francisco Corvus Pharmaceuticals, Inc. ยท Tests: Soquelitinib, Belinostat, Pralatrexate A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL NCT06854653Phase 215 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ New Haven Prescient Therapeutics, Ltd. ยท Tests: PTX-100 Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma NCT05996185Phase 22 sites๐Ÿ“ New Haven๐Ÿ“ New York Yale University ยท Tests: Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy